Skip to Content Skip to Search

Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GlaxoSmithKline. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

  • Q1 2022 figures are as at 22/04/2022
  • FY 2022-2026 figures are as at 21/03/2022
Please select...
£m (unless stated) Q122 Q122 n= 2022 2023 2024 2025 2026 2022-2026 n=
Turnover - Specialty Medicines ex pandemic solutions 1,801 16 8,118 9,109 10,123 11,039 11,799 14
Turnover - Vaccines ex pandemic solutions 1,465 16 7,247 7,920 8,766 9,587 10,268 14
Turnover - General Medicines 2,287 16 9,283 9,168 9,055 8,933 8,813 14
Turnover - GSK commercial operations excluding pandemic solutions 5,553 16 24,648 26,197 27,944 29,558 30,880 14
Turnover - Pandemic solutions 1,133 16 1,686 523 196 144 121 14
Turnover - GSK commercial operations 6,686 16 26,334 26,720 28,140 29,702 31,001 14
Turnover - Consumer Healthcare 2,465 16 9,916 10,291 10,674 11,064 11,467 14
Turnover -  Group 9,151 16 36,251 37,011 38,814 40,766 42,468 14
Cost of sales (3,191) 16 (11,318) (11,073) (11,381) (11,852) (12,303) 14
Selling, general and administration (2,560) 16 (10,837) (11,033) (11,337) (11,656) (11,986) 14
Research and Development (1,168) 16 (5,046) (5,250) (5,492) (5,746) (5,932) 14
Royalty income 127 16 566 622 390 415 432 14
Operating profit 2,359 16 9,617 10,277 10,994 11,927 12,679 14
Net finance costs (193) 16 (758) (728) (693) (650) (618) 14
Associates 3 16 4 4 4 4 4 14
Profit before tax 2,169 16 8,863 9,553 10,305 11,281 12,065 14
Taxation (393) 16 (1,600) (1,801) (1,961) (2,151) (2,300) 14
Tax Rate 18.1% 16 18.1% 18.8% 19.0% 19.1% 19.1% 14
Profit after tax  1,776 16 7,263 7,752 8,344 9,131 9,766 14
Minority interests (269) 16 (1,134) (1,209) (1,272) (1,332) (1,384) 14
Profit attributable to shareholders 1,507 16 6,129 6,543 7,072 7,799 8,381 14
WANS (m) 5,017 16 5,023 5,044 5,064 5,082 5,095 14
Earnings per share (p) 30.0 16 122.0 129.7 139.7 153.5 164.6 14
Dividend per share (p) 13.0 4 52.3 53.9 55.8 58.0 60.1 12
Free Cash Flow n/a n/a 5,117 5,436 5,905 6,583 7,057 10
Net Debt n/a n/a (17,737) (14,955) (11,773) (7,979) (3,956) 12
                 
USD / GBP 1.34 n/a 1.36 1.36 1.36 1.36 1.36 14
EUR / GBP 1.19 n/a 1.19 1.19 1.19 1.19 1.19 13
JPY / GBP 156 n/a 156 156 156 156 156 10

The firms included are: Bank of America, Barclays, Berenberg, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Intron Health, Jefferies, JP Morgan, Morgan Stanley, Morningstar, Redburn, UBS, Wolfe Research.

Turnover £m Q122 Q122 n= 2022 2023 2024 2025 2026 2022-2026 n=
                 
Tivicay 294 15 1,267 1,180 1,096 1,023 956 13
Triumeq 389 15 1,657 1,486 1,327 1,200 1,088 13
Juluca 126 16 566 606 640 666 689 14
Dovato 249 16 1,170 1,505 1,791 2,004 2,159 14
Dolutegravir based regimens 1,058 16 4,660 4,777 4,853 4,893 4,893 14
Cabotegravir +/- rilpivirine 30 16 214 472 783 1,082 1,318 14
Rukobia 16 16 91 130 162 185 205 14
Other HIV 26 16 95 82 75 74 80 14
HIV 1,130 16 5,060 5,461 5,873 6,234 6,495 14
                 
Benlysta 229 16 1,040 1,156 1,249 1,266 1,247 14
Nucala 295 16 1,319 1,444 1,540 1,608 1,648 14
                 
Zejula 110 16 496 608 706 797 880 14
Blenrep 29 16 145 240 335 418 493 14
Jemperli 4 16 30 66 100 133 161 14
                 
daprodustat - n/a 24 107 205 295 365 13
                 
Specialty Medicines ex pandemic solutions 1,801 16 8,118 9,109 10,123 11,039 11,799 14
                 
Xevudy 1,112 16 1,587 469 161 120 104 14
                 
Specialty Medicines 2,913 16 9,705 9,578 10,285 11,159 11,903 14

The firms included are: Bank of America, Barclays, Berenberg, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Intron Health, Jefferies, JP Morgan, Morgan Stanley, Morningstar, Redburn, UBS, Wolfe Research.

Turnover £m Q122 Q122 n= 2022 2023 2024 2025 2026 2022-2026 n=
Bexsero 147 15 713 754 776 790 803 14
Menveo 42 15 298 310 316 320 321 14
Other Meningitis 10 7 36 35 35 34 34 5
Meningitis 199 16 1,047 1,099 1,127 1,144 1,158 14
Fluarix/Flulaval 19 16 699 721 740 759 778 14
Shingrix 528 16 2,428 2,906 3,462 3,925 4,318 14
Boostrix 102 15 548 560 570 578 587 14
Cervarix 43 14 136 135 135 135 135 13
Hepatitis 109 15 512 556 579 599 614 14
Infanrix, Pediarix 137 15 538 536 537 540 543 14
Rotarix 119 15 556 561 568 575 582 14
Synflorix 104 15 360 358 354 345 340 14
Established Vaccines 719 16 3,072 3,124 3,171 3,210 3,240 14
Vaccines ex pandemic solutions 1,465 16 7,247 7,920 8,766 9,587 10,268 n/a
Pandemic solutions 21 16 100 54 34 23 17 14
Vaccines 1,486 16 7,346 7,974 8,800 9,610 10,285 14

The firms included are: Bank of America, Barclays, Berenberg, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Intron Health, Jefferies, JP Morgan, Morgan Stanley, Morningstar, Redburn, UBS, Wolfe Research.

Turnover £m Q122 Q122 n= 2022 2023 2024 2025 2026 2022-2026 n=
Anoro 120 16 519 530 537 541 545 14
Arnuity 8 16 50 50 51 52 52 14
Avamys/Veramyst 97 15 291 263 241 228 217 13
Flixotide/Flovent 104 16 393 366 345 326 308 14
Incruse 52 16 208 213 219 224 229 14
Relvar/Breo 260 16 1,070 1,069 1,070 1,066 1,064 14
Seretide/Advair 308 16 1,170 1,039 930 844 774 14
Trelegy 352 16 1,611 1,899 2,122 2,290 2,423 14
Ventolin 170 16 652 610 579 552 529 14
Respiratory 1,500 15 6,078 6,143 6,192 6,212 6,224 13
Other General Medicines 787 15 3,206 3,024 2,863 2,721 2,589 14
                 
General Medicines 2,287 16 9,283 9,168 9,055 8,933 8,813 14

The firms included are: Bank of America, Barclays, Berenberg, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Intron Health, Jefferies, JP Morgan, Morgan Stanley, Morningstar, Redburn, UBS, Wolfe Research.

Turnover £m Q122 Q122 n= 2022 2023 2024 2025 2026 2022-2026 n=
Oral Care 730 11 2,851 2,977 3,101 3,226 3,356 11
Pain Relief 584 11 2,359 2,447 2,538 2,633 2,731 11
Respiratory health 297 11 1,203 1,246 1,284 1,323 1,363 11
VMS 380 11 1,590 1,661 1,732 1,805 1,884 11
Digestive Health and other 474 9 1,868 1,926 1,989 2,050 2,108 11
Brands divested and under review - n/a 45 34 30 27 25 11
Consumer Health 2,465 16 9,916 10,291 10,674 11,064 11,467 14

The firms included are: Bank of America, Barclays, Berenberg, Cowen, Credit Suisse, Deutsche Bank, Exane, Guggenheim Securities, Intron Health, Jefferies, JP Morgan, Morgan Stanley, Morningstar, Redburn, UBS, Wolfe Research.

Back to top